Bullish case
$85 to $90
More likely if the Vertex deal closes on schedule in Q3 2026 and CRNX converges to the $85.00 cash consideration, or if a competing proposal forces a higher price. The highest analyst target is $90.
Crinetics Pharmaceuticals, Inc. research snapshot
CRNX AI Stock Analysis
CRNX AI stock analysis now reads Crinetics Pharmaceuticals as a company with a signed all-cash acquisition, not as an open-ended growth story. On July 6, 2026, Vertex Pharmaceuticals agreed to buy Crinetics for $85.00 per share in cash, about $10.0 billion in equity value, and the stock has traded just below the offer since. At the August 3, 2026 data cutoff, the latest close was $83.52 on July 31, 2026, the market capitalization was about $8.81 billion, and the main decision point is whether the deal completes in the expected third quarter of 2026 rather than what earnings multiple the stock deserves. This page uses scenario ranges, not a precise price promise, and is informational research, not investment advice.
Current price
$83.52
Market cap
$8.81 billion
AI score
79 / 100
Rating
Signed all-cash deal, completion drives returns
Trend status
Pinned near the $85 offer, rangebound
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level to B-level. Crinetics has public filings, analyst coverage, and dense news flow around the Vertex acquisition, but forward outcomes hinge on merger completion, regulatory clearances, and clinical readouts that are inherently uncertain.
- bias Check
- The main AI bias risk is anchoring to the $85.00 cash offer and treating completion as certain. The analysis separates verified deal terms, price, and financials from forward judgments about timing and break risk.
- ai Confidence
- High for price, market cap, deal terms, and financial statements cross-checked across SEC EDGAR filings and StockAnalysis.com. Medium for technical levels and completion timing.
- investment Certainty
- Medium. The cash offer defines a near-term outcome, but if the deal breaks, equity value depends on standalone pipeline and launch performance, so certainty is lower than data confidence.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | High for a clinical-to-commercial company: PALSONIFY is approved and ramping in acromegaly and atumelnant is in Phase 3 for CAH, but the company is still deeply loss-making. | High |
| Moat | Medium. First-mover oral nonpeptide position in acromegaly and ACTH antagonism in CAH, backed by clinical data, exclusivity, and specialist trust, but new mechanisms and entrants can narrow it. | Medium |
| Management | High. Founder-led team negotiated a full-cash $85.00 per share exit at about a 100% premium with unanimous board support and a $350.47M termination fee. | Medium-high |
| Financial trend | Improving revenue trajectory but persistent losses and dilution. Q1 2026 product revenue reached $10.31M versus $5.42M in Q4 2025, and cash and investments were about $1.29B at March 31, 2026. | High |
| Valuation | Event-driven. At $83.52 the stock embeds a high probability of completion of the $85.00 cash offer, so conventional earnings multiples are not the main driver. | Medium-high |
| Technical trend | Pinned in a tight band near the $85 offer with an RSI near 90. The 50-day moving average near $54 and the 200-day near $46 mark the deal-break reversion zone. | Medium |
| Risk level | Deal-completion risk dominates: the stockholder vote, HSR waiting-period expiration, and other regulatory clearances set the timing, and a break implies a return toward the $42 to $55 pre-announcement zone. | Medium-high |
| AI confidence | High for deal terms, price, market cap, and financials verified across SEC EDGAR and StockAnalysis.com. Medium for technical levels and completion timing. | Medium-high |
| Investment certainty | Medium. The cash offer defines a near-term outcome, but a deal break would leave holders with standalone pipeline value, so certainty is lower than data confidence. | Medium |
CRNX AI stock forecast
CRNX AI Stock Forecast Scenarios
The CRNX AI stock forecast is dominated by the pending all-cash acquisition by Vertex at $85.00 per share, announced on July 6, 2026 and expected to close in the third quarter of 2026. The scenarios below describe ranges around the July 31, 2026 close of $83.52, not precise predictions, and the main variable is deal completion rather than earnings growth.
Base case
$83.50 to $85
More likely if the deal stays on track, the stock continues to trade in a narrow band near the offer, and investors wait for the special stockholder meeting, regulatory clearances, and the Q2 2026 results scheduled for August 4, 2026.
Bearish case
$42 to $55
More likely if the deal is terminated or materially delayed by a failed stockholder vote, a regulatory denial, a material adverse change, or a financing failure, and the stock reprices toward the pre-announcement zone near the 200-day moving average of $46 and the 50-day moving average of $54.
CRNX AI technical analysis
CRNX AI Technical Analysis
CRNX AI technical analysis is dominated by the $85.00 cash offer. The stock closed at $83.52 on July 31, 2026, with a 52-week range of $25.83 to $84.00, a 50-day moving average near $54.06, a 200-day moving average near $46.02, and an RSI near 90. Because this static page does not fetch request-time chart data, live levels should be confirmed in a charting tool before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $83.52 at the July 31, 2026 close | The latest close available at the August 3, 2026 data cutoff. |
| Offer price | $85.00 per share in cash | The Vertex consideration is the reference value; the stock has traded just below it since the July 6, 2026 announcement. |
| Near resistance | $84.00 to $85.00 | The 52-week high near $84 and the $85 offer act as a ceiling while the deal is on track. |
| Near support | $80.00 to $83.50 | The recent trading band near the offer. A close below $80 would signal rising deal-break concerns. |
| Key support | $54.06 | The 50-day moving average is a deal-break reversion zone. |
| Major support | $46.02 | The 200-day moving average approximates the pre-announcement trend area. |
| Momentum | RSI near 90, overbought | The deal jump pushed momentum to extreme levels; it reflects a fixed cash outcome, not a durable rally. |
| Volume | About 8.8M shares per 20-day average | Volume spiked on the announcement and remains active, so single merger headlines can produce wide gaps. |
| Volatility | Low realized beta, high event risk | Beta near 0.23 masks binary gap risk tied to merger news, regulatory decisions, and the stockholder vote. |
| Invalidation | Close below $80 | A decisive close below $80 would weaken the convergence thesis; a break below the 50-day moving average near $54 would confirm reversion toward pre-deal levels. |
CRNX AI trading strategy
CRNX AI Trading Strategy Framework
The CRNX AI trading strategy is a rules-based research framework, not personalized advice. Because the stock is a pending cash acquisition, the setups focus on the spread to the $85.00 offer, deal-break risk, and the fundamentals that would matter if the deal did not close.
Merger arbitrage setup
Capture the spread between the current price near $83.52 and the $85.00 cash consideration by holding into the expected Q3 2026 close, while tracking the special meeting vote, HSR waiting-period expiration, and other regulatory clearances.
The spread is about 1.8% while a deal break could push the stock to $42 to $55, so cap position size and define an exit before entering; a close below $80 should trigger a reassessment.
Range and news trading
Trade the tight band between about $83 and $85, buying dips near the offer-adjacent support and selling into strength near the $85 ceiling when no deal news is pending.
Use tight stops below $80 and avoid leverage, because a single merger or regulatory headline can gap the stock.
Fundamental monitor
If the deal completes, the standalone thesis ends; if it breaks, watch PALSONIFY enrollment and reimbursement metrics, atumelnant Phase 3 (CALM-CAH and BALANCE-CAH) data, the Q2 2026 report on August 4, 2026, cash runway, and dilution.
Reduce confidence when price moves are driven by unverified merger rumors rather than official filings and regulatory announcements.
Investment research summary
Four-master Research Compression
Business essence
Crinetics Pharmaceuticals sells PALSONIFY, the first once-daily oral therapy approved for acromegaly (FDA in September 2025, European Commission in April 2026), and is developing atumelnant, an oral ACTH receptor antagonist in Phase 3 for congenital adrenal hyperplasia. Patients and physicians pay for endocrine disease control without injectable somatostatin analogues; Q1 2026 product revenue reached $10.31M, up from $5.42M in Q4 2025.
Moat
The moat rests on first-mover oral nonpeptide GPCR-targeting small molecules, clinical data, regulatory exclusivity, specialist trust, and IP. It is real but narrow: competing mechanisms and entrants, such as the CAH drug crinecerfont, can narrow the advantage, and the technology does not yet lock in the market.
Munger risk inversion
The thesis fails most obviously if the Vertex deal breaks: a failed stockholder vote, a regulatory denial, a material adverse change, or a financing failure could send the stock back toward the $42 to $55 pre-announcement zone. Standalone, the risks are a slow PALSONIFY launch, an atumelnant Phase 3 miss, new competition, or further dilution.
Management
Founder and CEO Scott Struthers built Crinetics from 2008 research into a commercial product and negotiated an all-cash $85.00 per share acquisition, about a 100% premium to the pre-deal price, with unanimous board support and a $350.47M termination fee protecting the deal. Key officers signed one-year post-close non-compete agreements, and incentives are aligned with closing the transaction.
Industry trend
Rare endocrine diseases are a durable specialty category, and oral small molecules are gradually replacing injectable biologics, a care-paradigm shift similar to earlier moves in diabetes and growth hormone therapy. Value still depends on clinical proof and launch execution, not on broad market narratives.
Valuation and margin of safety
At $83.52, the market cap is about $8.81B and the stock sits about 1.8% below the $85.00 cash offer, embedding a high probability of completion. The margin of safety comes from the fixed cash consideration, while the margin of error is the full downside toward standalone value if the deal breaks, making the risk-reward asymmetric and completion-dominated.
Source-backed data
CRNX Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $83.52 at the July 31, 2026 close | StockAnalysis.com CRNX quote | August 3, 2026 |
| Market capitalization | $8.81B, verified as $83.52 x 105.44M shares with 0.04% deviation | financial_rigor.py market cap verification | August 3, 2026 |
| Vertex acquisition offer | $85.00 per share all cash, about $10.0B equity value, about $8.8B net of estimated cash acquired, expected to close Q3 2026, not subject to a financing condition | SEC Form 8-K and joint Vertex-Crinetics press release | August 3, 2026 |
| Merger agreement terms | Deal deadline January 6, 2027 with a possible three-month extension; $350,474,425 termination fee payable by Crinetics under specified circumstances; non-solicitation with a superior proposal exception | SEC Form 8-K merger agreement summary | August 3, 2026 |
| FY2025 revenue | $7.70M, up 640.71% from $1.04M, composed of $5.42M product revenue and $2.28M collaboration and license revenue | StockAnalysis.com financials and SEC filings | August 3, 2026 |
| Q1 2026 revenue | $10.734M total revenue (product revenue $10.306M), up from $0.361M in Q1 2025 | SEC Form 10-Q for the quarter ended March 31, 2026 | August 3, 2026 |
| Q1 2026 net loss | $127.845M net loss, diluted EPS of -$1.23 | SEC Form 10-Q for the quarter ended March 31, 2026 | August 3, 2026 |
| FY2025 net loss | $465.32M net loss, diluted EPS of -$4.95 | StockAnalysis.com and SEC filings | August 3, 2026 |
| Cash and investments | About $1.291B at March 31, 2026, composed of $114.3M cash and $1.177B investment securities; funding sufficient for at least the next twelve months per management | SEC Form 10-Q for the quarter ended March 31, 2026 | August 3, 2026 |
| Q1 2026 capital raise | About $380.5M net raised from the issuance of common stock, contributing to a 12.58% year-over-year share increase | SEC Form 10-Q cash flow statement and StockAnalysis.com | August 3, 2026 |
| Shares outstanding | 105.31M at March 31, 2026 per the 10-Q, 105.44M per StockAnalysis.com on August 2, 2026 | SEC Form 10-Q and StockAnalysis.com statistics | August 3, 2026 |
| Analyst consensus | Hold with an average price target of $85.50 (low $85, median $85, high $90) across 14 analysts, revised to track the $85 offer | StockAnalysis.com forecast and analyst ratings | August 3, 2026 |
| Technical statistics | 52-week range $25.83 to $84.00, 50-day moving average $54.06, 200-day moving average $46.02, RSI near 90, beta 0.23 | StockAnalysis.com statistics | August 3, 2026 |
| Next earnings date | Q2 2026 results scheduled for August 4, 2026, after market close | StockAnalysis.com earnings calendar | August 3, 2026 |
Frequently Asked Questions
Read the Vertex Pharmaceuticals AI stock analysisUse Pineify AI Stock PickerBuild an AI trading strategyRun an AI stock screener
This CRNX AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 3, 2026, including the pending Vertex acquisition announced on July 6, 2026, and can be wrong if the deal changes or fails, or if new filings, market prices, company events, or macro conditions change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Open
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Open
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Open